PAMS
ITCI

Pictet Asset Management (Switzerland)’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$106M Buy
1,671,846
+490,242
+41% +$30.5M 0.13% 189
2023
Q1 		$64M Buy
1,181,604
+182,612
+18% +$8.83M 0.08% 255
2022
Q4 		$52.9M Buy
998,992
+154,068
+18% +$7.72M 0.08% 261
2022
Q3 		$39.3M Sell
844,924
-268,658
-24% -$14M 0.06% 309
2022
Q2 		$63.6M Sell
1,113,582
-371,906
-25% -$21.1M 0.09% 248
2022
Q1 		$90.9M Buy
1,485,488
+30,614
+2% +$1.59M 0.1% 231
2021
Q4 		$76.1M Buy
+1,454,874
New +$61.1M 0.08% 270

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s ITCI Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) increased its Intra-Cellular Therapies Inc. (ITCI) stake by 41% in Q2 2023, buying an estimated $30.5M and bringing the position to 1,671,846 shares worth $106M. The position accounts for 0.13% of the portfolio, ranked #189.

Pictet Asset Management (Switzerland) first reported a position in ITCI in Q4 2021 and has held it in 7 quarters since. 288 funds tracked by Wall St. Rank hold ITCI as of Q2 2023.

  • Pictet Asset Management (Switzerland) held 1,671,846 shares of Intra-Cellular Therapies Inc. worth $106M as of Q2 2023.
  • Pictet Asset Management (Switzerland) bought 490,242 Intra-Cellular Therapies Inc. shares in Q2 2023, an estimated $30.5M.
  • Intra-Cellular Therapies Inc. made up 0.13% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #189 holding.
  • Pictet Asset Management (Switzerland) first reported a position in Intra-Cellular Therapies Inc. in Q4 2021 and has held it in 7 quarters since.
  • 288 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.